Patient-specific pancreatic tumor neoantigens presented on MHC class I (PDAC neoantigens)

Patient-specific pancreatic tumor neoantigens presented on MHC class I are unique peptides derived from non-synonymous somatic mutations found exclusively within an individual's pancreatic cancer cells (Rojas et al., 2023, Nature). These antigens are processed intracellularly and displayed on the cell surface by Major Histocompatibility Complex (MHC) class I molecules, where they serve as targets for CD8+ cytotoxic T cells (Balachandran et al., 2017, Nature). Because these neoantigens are not expressed in healthy tissues, they provide a high degree of therapeutic specificity, reducing the risk of autoimmune-like toxicities (Luksza et al., 2017, Nature). In pancreatic ductal adenocarcinoma (PDAC), which typically has a low mutational burden, the identification of high-quality neoantigens is critical for transforming the immunosuppressive tumor microenvironment (PubMed: 37165196). Therapeutic interventions, such as personalized mRNA vaccines like Autogene cevumeran, are designed to stimulate the immune system to recognize these specific neoepitopes (BioNTech, 2023). Clinical studies have demonstrated that inducing neoantigen-specific T-cell responses can correlate with delayed tumor recurrence and improved survival in patients with resected pancreatic cancer (Rojas et al., 2023, Nature).

Other names

Personalized tumor neoantigensMHC-I restricted neoepitopesTumor-specific antigens (TSAs)Mutation-derived antigensPDAC neoepitopes

Induction of de novo neoantigen-specific CD8+ T-cell responses via personalized vaccination (mRNA or peptide) or adoptive transfer of TCR-engineered T cells.